大麻二酚在神经紊乱中的作用。
The Role of Cannabidiol in Neurological Disorders.
机构信息
Department of Neurology, Kaiser Permanente Medical Center, Orange County, CA.
出版信息
Perm J. 2021 May;25. doi: 10.7812/TPP/20.156.
Abstract
Cannabis has been used for both recreational and medicinal purposes for more than 4 millennia. Cannabis has been studied in various medical disorders including neurological disorders. There are well-known risks of long-term use of cannabis, including low motivation, lowered cognitive capabilities, and diminished IQ and brain mass. Cannabinoids are compounds in cannabis that are known to have therapeutic potential. The most abundant chemicals in cannabinoids are delta-9-tetrahydrocannabinol and cannabidiol. Delta-9-tetrahydrocannabinol has psychotropic effects that limits its use as a pharmacotherapeutic agent. Cannabidiol is a nonpsychotropic chemical and therefore has become a compound of interest for clinical researchers to study its therapeutic potential. This article reviews the efficacy and safety of cannabidiol in various neurological disorders in humans.
摘要
大麻已经被用于娱乐和医疗目的超过 4000 年。大麻已经在各种医学疾病中进行了研究，包括神经疾病。长期使用大麻有众所周知的风险，包括低动力、认知能力下降以及智商和大脑质量下降。大麻素是大麻中的化合物，已知具有治疗潜力。大麻素中最丰富的化学物质是 delta-9-四氢大麻酚和大麻二酚。Delta-9-四氢大麻酚具有致幻作用，限制了它作为药物治疗剂的使用。大麻二酚是一种非致幻化学物质，因此已成为临床研究人员研究其治疗潜力的化合物。本文综述了大麻二酚在人类各种神经疾病中的疗效和安全性。
相似文献
1
The Role of Cannabidiol in Neurological Disorders.
Perm J. 2021 May;25. doi: 10.7812/TPP/20.156.
2
Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies.
Gac Med Mex. 2019;155(5):471-474. doi: 10.24875/GMM.M20000334.
3
Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications.
J Integr Med. 2023 May;21(3):236-244. doi: 10.1016/j.joim.2023.03.004. Epub 2023 Mar 18.
4
Cannabinoids in epilepsy: clinical efficacy and pharmacological considerations.
Neurologia (Engl Ed). 2023 Jan-Feb;38(1):47-53. doi: 10.1016/j.nrleng.2020.02.012. Epub 2021 Nov 22.
5
Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions.
J Am Psychiatr Nurses Assoc. 2020 Sep/Oct;26(5):447-457. doi: 10.1177/1078390320929410. Epub 2020 Jun 6.
6
The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.
Epilepsy Behav. 2017 May;70(Pt B):288-291. doi: 10.1016/j.yebeh.2016.11.021. Epub 2017 Feb 4.
7
Constituents of Cannabis Sativa.
Adv Exp Med Biol. 2021;1264:1-13. doi: 10.1007/978-3-030-57369-0_1.
8
Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….
Headache. 2015 Jun;55(6):885-916. doi: 10.1111/head.12570. Epub 2015 May 25.
9
Cannabinoids: the lows and the highs of chemotherapy-induced nausea and vomiting.
Future Oncol. 2019 Mar;15(9):1035-1049. doi: 10.2217/fon-2018-0530. Epub 2019 Feb 5.
10
The current role of cannabis and cannabinoids in health: A comprehensive review of their therapeutic potential.
Life Sci. 2023 Sep 15;329:121838. doi: 10.1016/j.lfs.2023.121838. Epub 2023 Jun 7.
引用本文的文献
1
Development of a Validated LC-MS Method for the Determination of Cannabinoids and Evaluation of Supercritical CO vs. Ultrasound-Assisted Extraction in L. (Kompolti cv.).
Antioxidants (Basel). 2025 Jun 24;14(7):777. doi: 10.3390/antiox14070777.
2
Secondary metabolite profiles and anti-SARS-CoV-2 activity of ethanolic extracts from nine genotypes of Cannabis sativa L.
Arch Pharm (Weinheim). 2025 Jan;358(1):e2400607. doi: 10.1002/ardp.202400607. Epub 2024 Nov 14.
3
Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders.
Curr Pharm Des. 2025;31(8):630-644. doi: 10.2174/0113816128318194240918113954.
4
Assessing effects of Cannabis on various neuropathologies: A systematic review.
J Ayurveda Integr Med. 2024 May-Jun;15(3):100911. doi: 10.1016/j.jaim.2024.100911. Epub 2024 Jun 13.
5
Prescription Practices of Cannabinoids in Children with Cerebral Palsy Worldwide-A Survey of the Swiss Cerebral Palsy Registry.
Children (Basel). 2023 Nov 23;10(12):1838. doi: 10.3390/children10121838.
6
Efficacy and safety of medical cannabinoids in children with cerebral palsy: a systematic review.
Einstein (Sao Paulo). 2023 Nov 17;21:eRW0387. doi: 10.31744/einstein_journal/2023RW0387. eCollection 2023.
7
Investigating cannabinoids as P2X purinoreceptor 4 ligands by using surface plasmon resonance and computational docking.
Heliyon. 2023 Oct 21;9(11):e21265. doi: 10.1016/j.heliyon.2023.e21265. eCollection 2023 Nov.
8
Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review.
Behav Neurol. 2023 Oct 12;2023:8825358. doi: 10.1155/2023/8825358. eCollection 2023.
9
Cannabinoids in the Modulation of Oxidative Signaling.
Int J Mol Sci. 2023 Jan 28;24(3):2513. doi: 10.3390/ijms24032513.
10
Neurogenetic and Epigenetic Aspects of Cannabinoids.
Epigenomes. 2022 Aug 26;6(3):27. doi: 10.3390/epigenomes6030027.
本文引用的文献
1
Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid.
Epilepsia. 2020 Aug;61(8):e85-e89. doi: 10.1111/epi.16596. Epub 2020 Jul 2.
2
Short- and Long-Term Effects of Cannabis on Headache and Migraine.
J Pain. 2020 May-Jun;21(5-6):722-730. doi: 10.1016/j.jpain.2019.11.001. Epub 2019 Nov 9.
3
Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy.
Epilepsia. 2019 Aug;60(8):1586-1592. doi: 10.1111/epi.16093. Epub 2019 Jun 27.
4
Effects of cannabidiol on brivaracetam plasma levels.
Epilepsia. 2019 Jul;60(7):e74-e77. doi: 10.1111/epi.16071. Epub 2019 Jun 18.
5
Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis.
JAMA Netw Open. 2018 Oct 5;1(6):e183485. doi: 10.1001/jamanetworkopen.2018.3485.
6
Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.
Epilepsia. 2019 Feb;60(2):294-302. doi: 10.1111/epi.14628. Epub 2018 Dec 23.
7
Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet Neurol. 2019 Feb;18(2):155-164. doi: 10.1016/S1474-4422(18)30406-X. Epub 2018 Dec 13.
8
Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
CNS Drugs. 2019 Jan;33(1):47-60. doi: 10.1007/s40263-018-0589-2.
9
Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study.
J Autism Dev Disord. 2019 Mar;49(3):1284-1288. doi: 10.1007/s10803-018-3808-2.
10
Medical Use of Cannabinoids.
Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1.
Zotero 插件